Advertisement

Tumor Biology

, Volume 35, Issue 11, pp 11021–11025 | Cite as

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer

  • Yasuko Enomoto
  • Shin-ichi Yamashita
  • Yasuteru Yoshinaga
  • Yasuyoshi Fukami
  • So Miyahara
  • Kazuki Nabeshima
  • Akinori Iwasaki
Research Article

Abstract

This study investigated the potential of DYRK2, a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase gene, to predict disease-free survival for patients with early stage breast cancer. Two hundred and seventy-four patients with breast cancer underwent surgery from January 2000 to December 2009. All patients were in stage I or II. Immunohistochemical (IHC) analysis was used to determine the expression of DYRK2, which was examined for its association with clinicopathological factors or prognosis. A total of 85 of 274 cases (31 %) were DYRK2 positive. No correlation was found between DYRK2 expression by IHC and clinicopathological factors such as tumor size, histological grade, hormone receptor status, and HER2 status; however, lymph node involvement was closely associated with DYRK2 expression. Ten-year disease-free survival in the DYRK2-positive group without node metastasis (95.9 %) was significantly better than that in the DYRK2-negative group (87.3 %, p = 0.015). These data show that DYRK2 expression is associated with lymph node involvement and is a possible predictive factor of breast cancer recurrence.

Keywords

Breast cancer DYRK2 Prognostic factor 

Notes

Acknowledgments

The authors appreciate the technical support of Ms. Yoko Miyanari.

Conflicts of interest

None.

References

  1. 1.
    Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer. 1983;52:1551–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Mulligan JM, Hill LA, Deharo S, I Irwin G, Boyle D, Keating KE, Raji OY, McDyer FA, O’Brien E, Bylesjo M, Quinn JE, Lindor NM, Mullan PB, James CR, Walker SM, Kerr P, James J, Davison TS, Proutski V, Salto-Tellez M, Johnston PG, Couch FJ, Paul Harkin D, Kennedy RD. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. J Natl Cancer Inst. 2014 Jan;106(1)Google Scholar
  3. 3.
    Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7:340–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost HG. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J Biol Chem. 1998;273:25893–902.PubMedCrossRefGoogle Scholar
  5. 5.
    Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell. 2007;25:794–6.CrossRefGoogle Scholar
  6. 6.
    Pérez M, García-Limones C, Zapico I, Marina A, Schmitz ML, Muñoz E, et al. Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways. J Mol Cell Biol. 2012;4:316–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Taira N, Mimoto R, Kurata M, Yamaguchi T, Kitagawa M, Miki Y, et al. DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. J Clin Invest. 2012;122:859–72.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Jung HY, Wang X, Jun S, Park JI. Dyrk2-associated EDD-DDB1-VprBP E3 ligase inhibits telomerase by TERT degradation. J Biol Chem. 2013;288:7252–62.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Yamashita S, Chujo M, Tokuishi K, Anami K, Miyawaki M, Yamamoto S, et al. Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2009;138:1303–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Mimoto R, Taira N, Takahashi H, Yamaguchi T, Okabe M, Uchida K, et al. DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. Cancer Lett. 2013;339:214–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamashita S, Chujo M, Moroga T, Anami K, Tokuishi K, Miyawaki M, et al. DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer. Anticancer Res. 2009;29:2753–7.PubMedGoogle Scholar
  12. 12.
    Domagala W, Markiewski M, Harezga B, Dukowicz A, Osborn M. Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res. 1996;2:147–54.PubMedGoogle Scholar
  13. 13.
    Yoshida K. Role for DYRK family kinases on regulation of apoptosis. Biochem Pharmacol. 2008;76:1389–94.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yasuko Enomoto
    • 1
  • Shin-ichi Yamashita
    • 1
  • Yasuteru Yoshinaga
    • 1
  • Yasuyoshi Fukami
    • 1
  • So Miyahara
    • 1
  • Kazuki Nabeshima
    • 2
  • Akinori Iwasaki
    • 1
  1. 1.Department of General Thoracic, Breast, and Pediatric Surgery, Faculty of MedicineFukuoka UniversityFukuokaJapan
  2. 2.Department of Pathology, Faculty of MedicineFukuoka UniversityFukuokaJapan

Personalised recommendations